Schizophrenia is a common cause of incapacity and is ranked as the third-most-disabling illness subsequent to dementia and quadriplegia. Nearly, 75% of persons with schizophrenia have continuing ...

Background: Schizophrenia and bipolar disorder are chronic debilitating disorders that are often treated with second-generation antipsychotic agents, such as aripiprazole, quetiapine, and ziprasidone.

May 25, 2011 (Honolulu, Hawaii) — Switching from the atypical antipsychotics olanzapine, quetiapine, or risperidone to the atypical antipsychotic aripiprazole may reduce metabolic risk in patients ...

Please provide your email address to receive an email when new articles are posted on . Paliperidone 3-month LAI, aripiprazole LAI, olanzapine LAI and clozapine fared similarly to commonly used oral ...

The Appraisal Committee (section 8) considered evidence submitted by the manufacturer of aripiprazole and a review of this submission by the Evidence Review Group (ERG; section 9). 3.1 The ...

Management of bipolar disorder (BPD) may require multiple medications, including lithium, anticonvulsants, and antipsychotics (both conventional and atypical). Updated treatment guidelines reflect an ...

Patient preferences, adherence, real-world dosing, and other factors can affect the efficacy of treatment in usual clinical care and potentially limit the generalizability of clinical trial results to ...

White pills and a bottle Investigators examined 5-HT6 and 5-HT2A receptor availability in patients with schizophrenia who were treated with second-generation antipsychotic agents. A total of 9 men ...

The manufacturer presented direct clinical-effectiveness evidence from 2 randomised controlled trials comparing aripiprazole with placebo and performed a meta-analysis of these trials. The ...